Skip to content

Peptide Documentation Standards for Academic Labs

· Vertex Labs Editorial Team

A defensible peptide file for an academic lab begins with a batch-level Certificate of Analysis (COA) that includes the amino acid sequence, lot number, a full HPLC chromatogram with method parameters, and MS identity data traceable to a qualified analytical laboratory. That single document is the foundation of every reproducibility and compliance decision your lab will make downstream.

When a new peptide lot arrives, your immediate checklist should cover the following:

  • Match the lot number on the vial label to the lot number on the COA before anything else is recorded.
  • Inspect the COA for completeness: sequence, molecular weight (theoretical and observed), HPLC purity with a full chromatogram, MS identity confirmation, and the method parameters used.
  • Check the analytical lab identity: look for ISO 17025 accreditation, the analyst name, and the COA date.
  • Confirm traceability: the COA should reference traceable standards or pharmacopeial methods where applicable.
  • Perform a visual inspection of the vial (color, clarity, physical integrity) and document storage conditions on receipt.
  • Trigger in-house HPLC or LC-MS confirmation for critical lots, high-value assays, or any lot where the supplier COA is incomplete.

Pro Tip: Never accept a lone purity percentage as sufficient documentation. Verify the chromatogram shape and confirm the MS mass match independently. A number without supporting data is not evidence.

Table of Contents

1. What a credible peptide COA must contain

A COA is only as useful as the information it actually reports. A document that lists a purity percentage without the underlying chromatogram, or an MS result without observed m/z values, gives you no way to verify the claim independently. The following fields are the minimum standard for research-grade peptide documentation.

Product identification and physical description

  • Peptide name and amino acid sequence (one-letter or three-letter code)
  • Salt form and counterion (e.g., TFA salt, acetate salt)
  • Theoretical molecular weight and molecular formula
  • Catalog number and lot/batch number
  • Date of analysis and analyst or lab identity with contact information

Analytical evidence

  • HPLC purity expressed as area percent, with the full chromatogram embedded or attached
  • Method parameters: column type and dimensions, particle size, gradient program, mobile phase composition, flow rate, detection wavelength, and injection volume
  • MS identity: observed molecular mass vs. theoretical, adduct notation, charge states, and instrument type used
  • MS spectra (not just a statement of “confirmed by MS”)

Content metrics

  • Net peptide content or peptide-by-mass (distinct from HPLC area percent)
  • Residual counterion or TFA content
  • Water content (Karl Fischer or equivalent)
  • Residual solvent or endotoxin data where the application requires it

Traceability and accountability

  • ISO 17025 accreditation number for the testing laboratory
  • Third-party testing notation when applicable
  • Retention sample policy statement
  • Signed authorization or QA release signature

A complete research COA must include lot number, HPLC purity with chromatogram, MS mass match, and method parameters so results are reproducible across labs. Each field serves a specific function: the lot number ties the document to a physical batch; the method parameters allow you to reproduce or challenge the analysis; the analyst identity creates accountability. Missing any one of these fields forces you to make assumptions your SOP should not permit.

Pro Tip: Request the COA as a PDF with embedded chromatogram images at sufficient resolution to inspect integration markers and minor peaks. A compressed or low-resolution image obscures the impurity profile.

Clean COA documents and glass vials on lab bench

2. How to read HPLC chromatograms and avoid common purity pitfalls

HPLC purity reported as area percent is not the same as absolute peptide content. Residual TFA and moisture reduce net peptide content compared to HPLC area percent, and a COA reporting purity but not net peptide content is incomplete for quantitative laboratory work. Understanding this distinction is the first step to interpreting any chromatographic result correctly.

Lab bench with HPLC chromatogram and analytic instruments

Chromatographic purity vs. peptide mass fraction

Area percent purity reflects the proportion of the UV-absorbing signal attributed to the main peak relative to all detected peaks. It does not account for non-UV-absorbing counterions, water, or residual solvents. The net peptide content can be significantly lower than the HPLC purity once these factors are included. For dose-response studies or quantitative binding assays, this gap is material.

Method parameters that change interpretation

The following parameters must appear on the COA for the purity figure to be meaningful:

  • Column type and dimensions: reversed-phase C18 columns are standard, but particle size and pore diameter affect resolution of closely eluting impurities.
  • Gradient program: a shallow gradient resolves more impurities than a steep one; a steep gradient can merge peaks and inflate apparent purity.
  • Detection wavelength: 214 nm detects the peptide bond and is standard; 220 nm or 254 nm will give different relative responses for aromatic-containing peptides. An unreported wavelength makes the purity figure unverifiable.
  • Mobile phases: typically water/acetonitrile with 0.1% TFA or formic acid; deviations affect retention and peak shape.
  • System suitability data: tailing factor, resolution between reference peaks, and repeatability confirm the instrument was performing within specification on the day of analysis. USP <621> specifies system suitability and chromatographic method expectations used as a reference even for research-grade material.

Reading the chromatogram itself

When you open a chromatogram, check the following in order:

  1. Retention time of the main peak: consistent with the peptide’s hydrophobicity and the gradient used.
  2. Peak symmetry: a tailing factor above 2.0 suggests column degradation, co-eluting impurities, or poor injection conditions.
  3. Baseline separation of impurity peaks: peaks that are not fully resolved to baseline are often under-integrated, inflating the main-peak area percent.
  4. Integration markers: confirm that the software has correctly assigned the start and end of each peak; manual reintegration by a vendor is a known source of inflated purity.
  5. Minor peaks: any peak above 0.1% area should be identified or at least flagged; a clean chromatogram with no minor peaks at all can itself be a sign of over-compressed scaling.

Pro Tip: For critical lots, run a quick in-house RP-HPLC check on receipt using your own validated column and gradient. Your method may resolve impurities that the supplier’s method missed, particularly if the supplier used a steep gradient or a non-standard wavelength.

3. Identity confirmation by mass spectrometry: what to expect and where MS alone falls short

Mass spectrometry confirms that the observed molecular mass matches the theoretical mass of the claimed sequence. It does not, on its own, confirm purity or sequence order. Pairing MS with chromatographic separation is the standard approach to verify both identity and purity simultaneously.

What a COA should report for MS identity

  • Instrument type: ESI-MS, MALDI-TOF, or LC-MS (each has different mass accuracy and ionization characteristics).
  • Observed m/z values with charge state notation (e.g., [M+H]⁺, [M+2H]²⁺).
  • Theoretical molecular mass calculated from the sequence and modifications.
  • Mass accuracy: the difference between observed and theoretical mass, expressed in Da or ppm. For ESI-MS on a quadrupole instrument, ±0.5 Da is typical; high-resolution instruments (Orbitrap, Q-TOF) can achieve sub-ppm accuracy.
  • Adduct notation: sodium and potassium adducts are common and must be identified to avoid misassignment.

Molecular & Cellular Proteomics guidelines for targeted MS measurements require that authors report instrument type, observed m/z, and mass accuracy so reviewers can independently assess reliability. The same principle applies to COA documentation: a statement of “confirmed by MS” with no spectra or m/z values is not verifiable.

Interpretation limits

MS confirms mass, not sequence order. Two peptides with the same amino acid composition but different sequences (sequence isomers) will produce identical molecular masses. Detecting sequence isomers requires MS/MS fragmentation (tandem MS), which is not routinely included in standard COA testing. Near-isobaric impurities, where a contaminant has a mass within the instrument’s resolution window, can also go undetected by low-resolution MS.

Red flags on a COA MS section:

  • MS result reported only as a pass/fail statement with no spectra or m/z values
  • Missing instrument type or mass accuracy
  • No report of observed m/z for multiply charged species on larger peptides
  • No adduct identification

Pro Tip: Request LC-MS data that links retention times to mass traces. When you can see that the dominant chromatographic peak corresponds to the claimed mass, you have both purity and identity evidence in a single run, which is far more informative than separate HPLC and MS reports.

4. Third-party testing, reference standards, and traceability

A COA issued by the same laboratory that synthesized the peptide is a self-reported document. ISO 17025 accreditation and third-party testing are strong trust signals because they introduce independence and demonstrated analytical competence. When to require them depends on your experimental risk profile.

When to require third-party or independent testing

  • New suppliers: before placing a standing order, require at least one lot with a third-party COA from an ISO 17025-accredited laboratory.
  • High-risk assays: quantitative dose-response studies, receptor binding assays, or any experiment where peptide content directly affects the interpretation of results.
  • Clinical bridging studies: any work that will inform a regulated submission or patient-adjacent application requires GMP-grade documentation, not just third-party RUO testing.
  • Discrepant results: when your in-house QC does not match the supplier COA, an independent retest from an accredited lab is the appropriate next step.

Reference standards and traceability

The choice of reference standard materially affects comparability across labs. COAs that reference traceable, pharmacopeial or externally validated standards increase cross-lab reliability. In practice, this means the COA should state which reference standard was used for system calibration and whether it is traceable to a recognized authority such as the United States Pharmacopeia (USP) or NIST.

USP maintains a catalog of peptide reference standards that labs can use for system suitability and method validation. Where a USP standard exists for your peptide or a structurally similar compound, requesting that the supplier’s COA reference USP methods (e.g., USP <621> for chromatography) is a reasonable and defensible requirement.

Practical checks to run when evaluating a supplier’s accreditation:

  • Request the ISO 17025 accreditation certificate and scope of accreditation (confirm the relevant test methods are within scope).
  • Ask for proficiency testing records or inter-laboratory comparison data.
  • Confirm whether the COA references USP or pharmacopeial methods for chromatographic testing.
  • Verify the accreditation number against the accrediting body’s public registry (A2LA, NVLAP, or equivalent).

Pro Tip: Maintain a short list of trusted independent analytical labs for retention-sample confirmation. When a supplier COA is incomplete or a lot produces anomalous in-house results, having a pre-qualified external lab shortens the resolution timeline significantly.

5. Laboratory documentation standards for academic labs: file structure and retention

Good documentation practice in an academic lab is not about bureaucratic overhead. It is about being able to reconstruct exactly what material was used in an experiment, at what purity, and under what storage conditions, months or years after the work was done. The following structure gives lab managers a practical starting point.

Infographic outlining peptide documentation process steps

Link every incoming lot to a single folder or ELN record that contains:

  1. Purchase order or procurement record (supplier, catalog number, quantity, price)
  2. COA PDF (original, unmodified)
  3. HPLC chromatogram file (raw instrument data, not just the exported image)
  4. MS spectra file (raw or exported, with m/z table)
  5. In-house QC data if confirmatory testing was performed
  6. Receipt checklist (lot match, visual inspection, storage date, assigned identifier)
  7. Any vendor correspondence related to the lot (queries, responses, corrective actions)

Metadata to capture for each lot

  • Supplier name and address
  • Catalog number and lot/batch number
  • COA date and analyst name
  • Storage start date and assigned storage location
  • LIMS or ELN identifier (barcode or alphanumeric)
  • Assigned acceptance status (accepted, quarantined, rejected) with date and authorizing researcher

Retention-sample practice and linking COAs to raw data reduces risk and supports inter-lab reproducibility. Keep a labeled aliquot or vial from each lot in a designated retention-sample storage location, and record its identifier in the ELN alongside the COA.

Retention timelines

Align retention periods with your institution’s data management policy and the funding agency’s requirements. As a working rule, retain all analytical raw data and COAs for the full project lifecycle plus any post-publication period required by the journal or funder. NIH data management and sharing policies, updated in 2023, require that data supporting published findings be retained and accessible. For peptide lots used in published experiments, the COA and associated raw data are part of that record.

Pro Tip: Mandate a single-source folder convention: one folder per lot, named with the format [SupplierCode][CatalogNo][LotNo]_[DateReceived]. Every file related to that lot lives in that folder. This eliminates the most common documentation failure: raw data files that cannot be matched to a specific lot after the fact.

6. Electronic records and data integrity: practical 21 CFR Part 11 controls for academic labs

21 CFR Part 11 requires secure, auditable electronic records and controls to protect against unauthorized alteration throughout retention periods. While Part 11 formally applies to FDA-regulated submissions, its principles define the floor for defensible electronic recordkeeping in any U.S. research lab that may contribute data to a regulated context.

Core Part 11 principles that apply to research labs

  • Audit trails: computer-generated, time-stamped records of every creation, modification, or deletion of an electronic record. Your ELN or LIMS must log these automatically.
  • Role-based access: only authorized personnel can create, modify, or delete records. Access levels should match job function.
  • Validated systems: the software used to capture and store records should be validated for its intended use, with documented evidence of that validation.
  • Electronic signatures: where used in place of handwritten signatures (e.g., QA release), they must be linked to the signer’s identity and time-stamped.

Implementable controls for academic labs

  • Deploy an ELN (e.g., LabArchives, Benchling, or LabVantage) with built-in audit logging and role-based permissions.
  • Capture instrument data directly from the HPLC or MS system to a secured, append-only folder; do not allow manual overwriting of raw files.
  • Use encrypted, backed-up cloud or institutional server storage with access logs.
  • Require multi-factor authentication (MFA) for ELN and LIMS access.
  • Write and enforce an SOP for electronic record edits: any correction must be documented as an amendment with the original record preserved.

For smaller academic labs without enterprise LIMS infrastructure, validated cloud ELN providers offer a practical path to Part 11-aligned recordkeeping without the overhead of on-premise server management. A double-check sign-off workflow (primary researcher records, supervisor reviews and countersigns electronically) satisfies the core intent of the regulation for most research contexts. The batch testing workflow for peptide lots integrates naturally with this kind of ELN-based record structure.

Pro Tip: Require that any vendor COA delivered electronically include embedded metadata or a file checksum. Store the original PDF as the immutable evidence file and never overwrite it. If you need to annotate a COA, create a separate annotation document and link it to the original.

7. How to set acceptance criteria for research-grade peptides

Acceptance criteria translate a supplier’s COA data into a go/no-go decision for your lab. The right criteria depend on your experimental risk tolerance, not on a universal standard. A peptide used in an exploratory western blot tolerates more uncertainty than one used in a quantitative receptor binding assay.

  • Exploratory or qualitative assays: HPLC purity ≥95% area percent; MS identity confirmed (observed mass within ±0.5 Da of theoretical); net peptide content reported (any value accepted for exploratory use, but recorded).
  • Quantitative or dose-response assays: HPLC purity ≥98% area percent; net peptide content ≥80% by mass (or per your assay’s sensitivity); MS identity confirmed with instrument type and m/z reported; method parameters fully documented.
  • Critical or translational work: all of the above plus third-party COA from an ISO 17025-accredited lab; endotoxin testing result; retention sample confirmed.

Verification sampling plans

You do not need to confirm every lot in-house for every application. A practical approach:

  • Run confirmatory in-house HPLC for a defined subset of incoming lots (e.g., every third lot from an established supplier, every lot from a new supplier).
  • Perform full confirmatory testing (HPLC + LC-MS) for any lot designated for a critical or quantitative study.
  • Trigger immediate independent retesting for any lot where in-house results deviate from the COA by more than your defined tolerance.

Out-of-spec results: what to do

When a lot fails acceptance criteria, the response must be documented:

  1. Quarantine the lot immediately and label it clearly.
  2. Notify the supplier in writing with the specific discrepancy and your COA data.
  3. Send a retention sample to an independent accredited lab for confirmation.
  4. Document the corrective action taken (return, replacement, or rejection) in the ELN record for that lot.
  5. Update the vendor-evaluation scorecard with the incident.

Pro Tip: Write your acceptance criteria into the SOP before the first lot arrives, not after a problem occurs. Link the criteria explicitly to experiment type so any lab member can apply the rule without judgment calls. Document the rationale for each threshold in the SOP itself.

8. Research-Use-Only vs. GMP peptides: documentation differences and when GMP is required

Research-grade peptides undergo identity testing by MS and purity testing by HPLC, while GMP-grade materials are produced under validated, audited manufacturing with full documentation. The documentation gap between the two is substantial, and choosing the wrong grade for your application creates either unnecessary cost or genuine regulatory risk.

Documentation differences

Documentation element RUO (research-grade) GMP-grade
COA scope Identity, purity, net content Identity, purity, content, sterility, endotoxin, residual solvents
Method validation Not required; method parameters reported Full ICH Q2(R1) validation required
Manufacturing records Batch synthesis notes Full batch manufacturing record (BMR)
Facility audit Not required Regulatory inspection (FDA, EMA, or equivalent)
Stability data Not typically included Required for defined shelf life
Regulatory traceability Lot number and COA Full chain of custody, deviation records

Decision rules for RUO vs. GMP

Use this checklist when selecting material grade for a new project:

  • In-vitro cell-based or biochemical assays with no patient exposure: well-documented RUO with an independent COA is acceptable.
  • Animal studies under IACUC oversight: RUO is generally acceptable; confirm with your institution’s veterinary and compliance office.
  • Translational or clinical bridging studies: require GMP-grade material with full batch records and regulatory inspection history.
  • Compounding pharmacy supply chains or any application where patient exposure is possible: GMP is mandatory; RUO material is not appropriate regardless of purity.
  • Regulated submissions (IND, NDA, or equivalent): GMP documentation is required by FDA.

Vertexpeptideslab supplies research-use-only material. For any application that falls into the GMP-required categories above, the appropriate path is a GMP-certified manufacturer with full regulatory documentation. For in-vitro and preclinical research applications, manufacturing quality benchmarks and batch-level COA documentation are the relevant standards to apply.

9. Annotated COA walkthrough: reading a Vertexpeptideslab COA structure

Walking through a COA field by field is the most direct way to train lab staff and standardize intake decisions. The following annotated structure reflects the documentation format used by Vertexpeptideslab and illustrates how to interpret each section.

Field-by-field interpretation

Product identification block

  • Peptide name and sequence: confirms you received the correct compound. Cross-reference the sequence against your purchase order and the original literature source.
  • Salt form: TFA salt is the most common; acetate salt is preferred for cell-based assays because TFA can be cytotoxic at higher concentrations. The salt form affects net peptide content calculations.
  • Lot/batch number: this is the traceability anchor. Every downstream record (ELN entry, storage log, experimental notebook) must reference this number.

HPLC section

  • Purity (area %): the primary purity metric. Check that the method parameters (column, gradient, wavelength) are reported alongside it.
  • Chromatogram: look for a dominant main peak with baseline-resolved minor peaks. A chromatogram with no visible minor peaks at a compressed Y-axis scale warrants a request for the full-scale view.
  • Method parameters: if the wavelength is not 214 nm, note it. If the gradient is steeper than 1–2% organic per minute, minor impurities may be co-eluting with the main peak.

MS section

  • Observed vs. theoretical mass: a match within ±0.5 Da (low-resolution ESI-MS) or sub-ppm (high-resolution) confirms identity. Record both values in your ELN.
  • Charge states: larger peptides (>1,500 Da) typically show multiply charged species. Confirm that the reported m/z values are consistent with the expected charge distribution.
  • Instrument type: note whether ESI-MS, MALDI-TOF, or LC-MS was used. LC-MS provides both retention time and mass, which is the most informative combination.

Net peptide content

  • This field is distinct from HPLC area percent. A peptide at 98% HPLC purity may carry a net peptide content of 80% or lower depending on counterion and moisture load. For quantitative assays, use the net peptide content value to calculate working concentrations, not the area percent figure. High chromatographic purity does not guarantee equivalent peptide mass fraction; amino acid analysis or content reporting is preferable for quantitative work.

Common scenarios and responses

COA scenario Interpretation Action
High area % purity, no net peptide content reported Incomplete for quantitative use Request net content data from supplier
MS reported as “confirmed” with no m/z values Unverifiable identity claim Request full MS spectra with observed m/z
Chromatogram shows unresolved shoulder on main peak Possible co-eluting impurity Request higher-resolution chromatogram or in-house retest
Method parameters missing from COA Purity figure cannot be independently assessed Request full method details before accepting lot
No analyst name or lab identity No accountability trail Request lab identity and accreditation number

For examples of quality peptide lab reports and annotated COA structures, Vertexpeptideslab provides documentation resources that lab staff can use for training and intake standardization.

Pro Tip: When a COA gap requires a supplier query, use specific, written language: “Please provide the full HPLC chromatogram with method parameters (column, gradient, wavelength) and the observed m/z values from MS identity testing for Lot [number].” Specific requests get specific responses and create a documented record of the exchange.

10. Ready-to-use intake checklist, SOP snippets, and vendor-evaluation scorecard

The following templates are designed to be copied directly into your lab’s SOP or ELN intake workflow. Adapt the thresholds to match your institutional requirements and experimental risk profile.

Peptide lot intake checklist

  1. Confirm vial label lot number matches COA lot number.
  2. Inspect vial for physical integrity (no cracks, no visible contamination, correct fill volume or mass).
  3. Record receipt date, storage location, and temperature on the ELN intake form.
  4. Scan or photograph the COA and upload to the designated lot folder.
  5. Verify COA completeness: sequence, lot number, HPLC purity with chromatogram, MS identity, method parameters, net peptide content, analyst identity.
  6. Check HPLC purity against acceptance criteria for the intended application.
  7. Confirm MS identity: observed mass within tolerance of theoretical.
  8. Assign acceptance status (accepted / quarantined / rejected) and record in ELN.
  9. Label a retention aliquot and store in the designated retention-sample location.
  10. Link the lot folder (COA, raw data, intake form) to the relevant project record in the ELN.

SOP snippet: COA handling and retention

SOP snippet: retention-sample policy

File-naming convention

Use the following format for all lot-related files:

[SupplierCode]_[CatalogNo]_[LotNo]_[YYYYMMDD]_[FileType]

Examples:

  • VPL_TB500_LOT2024001_20240315_COA.pdf
  • VPL_TB500_LOT2024001_20240315_HPLC_raw.cdf
  • VPL_TB500_LOT2024001_20240315_MS_spectrum.pdf

Vendor-evaluation scorecard

Criterion Weight Scoring notes
COA completeness (all minimum fields present) High Pass/fail; incomplete COA = immediate flag
HPLC chromatogram provided with method parameters High Pass/fail
MS identity with observed m/z reported High Pass/fail
Net peptide content reported Medium Pass/fail for quantitative applications
ISO 17025 accreditation of testing lab High Verify against accrediting body registry
Third-party testing available on request Medium Yes/No
Responsiveness to documentation queries Medium Score 1–5 based on response time and quality
Retention-sample policy stated Medium Yes/No
Consistent lot-to-lot COA format Low Score 1–5

For a structured approach to vendor evaluation criteria, Vertexpeptideslab provides guidance on qualifying suppliers against documentation and QA benchmarks relevant to academic research.

11. Key actions every academic lab should take now

Rigorous peptide documentation standards for academic labs require batch-level COAs with chromatograms and MS data, an intake SOP that links each lot to a LIMS or ELN record, and risk-based acceptance criteria with independent testing for critical applications.

Point Details
Require batch-level COAs Every lot must include sequence, lot number, HPLC chromatogram with method parameters, and MS identity with observed m/z.
Implement an intake SOP Link each COA to its lot folder, ELN record, and raw instrument data before the material enters active use.
Set risk-based acceptance criteria Define purity and content thresholds by experiment type (exploratory vs. quantitative) and document the rules in the SOP.
Apply Part 11-aligned electronic controls Use an ELN or LIMS with audit trails, role-based access, and encrypted backups for all COA and raw-data storage.
Vertexpeptideslab documentation Vertexpeptideslab provides batch-level COAs with chromatogram and MS data, supporting traceable, research-grade peptide procurement.

For laboratory research use only. Not for human or veterinary use.

Documentation transparency is more than a compliance exercise

There is a tendency in academic research to treat COA review as a procurement formality: the document arrives, someone glances at the purity number, and the vial goes into the freezer. That approach creates a reproducibility liability that surfaces months later, when an experiment fails to replicate and no one can determine whether the peptide lot, the assay conditions, or the analytical method was the variable.

The documentation standards described here are not regulatory overhead imposed from outside the lab. They are the practical infrastructure that makes experimental data defensible. When a reviewer asks how you know the peptide you used was what you claimed it was, the answer is in the COA, the chromatogram, the MS trace, and the ELN record that links them all to the specific experiment. Without that chain, the answer is “we trusted the supplier,” which is not a scientific answer.

There is also a subtler point worth making about net peptide content. Most labs that use peptides in quantitative assays have never calculated the difference between HPLC area percent and actual peptide mass in their working solution. The gap can be 15–20% or more for TFA-salt peptides with significant moisture content. That gap does not show up in the purity number. It shows up in the dose-response curve, in the EC50 that does not match the literature, and in the inter-lab variability that makes a finding hard to reproduce. Requesting net peptide content on every COA is not a bureaucratic demand. It is the only way to know what concentration you are actually working with.

The evidence-based protocols that underpin reproducible peptide research consistently point to the same gap: documentation practices lag behind analytical capabilities. Labs that close that gap produce more reproducible data and spend less time troubleshooting anomalous results.

Vertexpeptideslab provides documented, research-grade peptides for academic labs

Documented peptide procurement should not require a separate project. Vertexpeptideslab supplies research-use-only peptides with batch-level COAs that include full HPLC chromatograms, method parameters, and MS identity data, so your lab’s intake checklist has something substantive to work with from the first lot.

Vertexpeptideslab

Each COA is linked to the specific lot, with purity verified through third-party testing where applicable and net peptide content reported alongside HPLC area percent. For labs updating their intake SOPs or evaluating new suppliers against the documentation standards described here, Vertexpeptideslab’s sequence characterization methods and quality benchmarks guide provide a direct reference for what rigorous analytical documentation looks like in practice. Contact technical support for COA questions, retention-sample requests, or documentation queries related to specific lots.

For laboratory research use only. Not for human or veterinary use.

Primary references and standards for peptide documentation

The following sources are the authoritative starting points for labs developing or updating peptide documentation policies.

Analytical and method standards

  • USP Peptide Reference Standards: the USP catalog of peptide standards and general chapters (including USP <621> for chromatography) relevant to method suitability and reference standard traceability.
  • ICH Quality Guidelines: ICH Q2(R1) (method validation), Q6A (specifications for chemical substances), and Q7 (GMP for active pharmaceutical ingredients) frame the documentation and validation expectations for peptide testing in regulated contexts.
  • Molecular & Cellular Proteomics targeted MS guidelines: the journal’s requirements for reporting targeted mass spectrometry measurements of peptides, including instrument type, observed m/z, and mass accuracy. Directly applicable to COA MS reporting standards.

Regulatory and data integrity

  • 21 CFR Part 11 (eCFR): the FDA’s electronic records and electronic signatures regulation. The principles apply to any U.S. lab maintaining electronic COA and raw-data records that may contribute to a regulated submission.
  • NIH Data Management and Sharing Policy (effective 2023): governs retention and accessibility of research data, including analytical records, for NIH-funded projects.

Practical COA and QC references

  • Peptide quality control and laboratory practices: a handbook-style overview of HPLC, MS, and GLP-aligned practices for peptide QC and handling.
  • Reference standards for synthetic peptide therapeutics: peer-reviewed discussion of how reference standard choice affects cross-lab comparability, with direct relevance to traceability requirements on COAs.
  • The Peptide Guide: research insights: educational resource covering peptide QC, protocols, and documentation best practices for research labs.

For routine research labs: prioritize USP <621>, the MCP targeted MS guidelines, and the NIH data management policy as the three documents most likely to affect your current SOP.

For translational or regulated work: add ICH Q2(R1), ICH Q7, and 21 CFR Part 11 as the framework for method validation, GMP documentation, and electronic records requirements.